Quanta Vision Co., Ltd. – Trademark Portfolio
Entity Type: 03
Quanta Vision Co., Ltd. has 4 U.S. trademark filings recorded with the United States Patent and Trademark Office (USPTO). Of these, 4 are successfully registered — a 100% registration rate. The portfolio includes marks such as D DRUG DOG. Filings span 4 Nice Classification classes, with the highest activity in Class 35 (Advertising & Business) and Class 1 (Chemicals). This trademark owner is based in New Taipei City.
9F., No. 527
Zhongzheng Rd., Xindian Dist.
New Taipei City 231 , TW
Showing of trademarks Trademarks
Trademark Classifications
Quanta Vision Co., Ltd.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Quanta Vision Co., Ltd. have?
Quanta Vision Co., Ltd. has 4 U.S. trademarks filed with the USPTO. Of these, 4 registered.
What trademark classes does Quanta Vision Co., Ltd. file in?
Quanta Vision Co., Ltd. files trademarks across 4 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 1 (Chemicals), Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals). Class 35 covers advertising; business management; business administration; office functions.
What are Quanta Vision Co., Ltd.'s most well-known trademarks?
Quanta Vision Co., Ltd.'s registered trademark portfolio includes well-known marks such as D DRUG DOG. These are among 4 currently registered trademarks in the portfolio.
What is Quanta Vision Co., Ltd.'s trademark registration success rate?
Quanta Vision Co., Ltd. has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.